Waverley Pharma（5GZ）株式概要バイオ医薬品会社であるウェイバリーファーマ社は、英国でがん治療薬の研究、開発、商業化を行なっている。 詳細5GZ ファンダメンタル分析スノーフレーク・スコア評価2/6将来の成長0/6過去の実績0/6財務の健全性0/6配当金0/6リスク分析マイナスの株主資本 キャッシュランウェイが1年未満である 意味のある時価総額がありません ( €337K )収益が 100 万ドル未満 ( CA$1M )+2 さらなるリスクすべてのリスクチェックを見る5GZ Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.NEW480,107 membersJoin community and earn perksGain real feedbackFrom our editorial team, personally. Not silence.Grow your followingReal investors. The kind who actually invest, not scroll past.Unlock free accessFree premium subscription for consistent and quality authors.Learn moreCreate NarrativeBLINRODA480,107 investors already sharing narrativesYour Fair Value€Current Price€0.00477.8% 割安 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-3m2m2016201920222025202620282031Revenue CA$550.7kEarnings CA$98.9kAdvancedSet Fair ValueView all narrativesWaverley Pharma Inc. 競合他社bioXXmedSymbol: DB:T5OMarket cap: €231.1kEpigenomicsSymbol: DB:ECXMarket cap: €824.4kGenetic AnalysisSymbol: DB:8V8Market cap: €46.2m2investSymbol: XTRA:2INVMarket cap: €62.9m価格と性能株価の高値、安値、推移の概要Waverley Pharma過去の株価現在の株価CA$0.00452週高値CA$0.01252週安値CA$0.004ベータ1.151ヶ月の変化-60.00%3ヶ月変化0%1年変化-50.00%3年間の変化-63.64%5年間の変化-96.00%IPOからの変化-95.79%最新ニュースお知らせ • Jul 18Waverley Pharma Inc. Announces CFO Changes, Effective July 24, 2026Waverley Pharma Inc. announced that Haaris Uddin is resigning from his role as Chief Financial Officer (CFO) of the Company effective July 24, 2026 in order to pursue a professional opportunity outside the pharmaceutical industry. James Kinley, who is currently a director of the Company, has been named interim CFO and will assume the duties of Mr. Uddin upon his departure. Mr. Kinley is a Chartered Professional Accountant (CPA, CA) and an experienced CFO in the life science industry.Reported Earnings • May 24First quarter 2026 earnings released: CA$0.003 loss per share (vs CA$0.001 loss in 1Q 2025)First quarter 2026 results: CA$0.003 loss per share (further deteriorated from CA$0.001 loss in 1Q 2025). Revenue: CA$287.1k (down 27% from 1Q 2025). Net loss: CA$165.5k (loss widened 359% from 1Q 2025). Over the last 3 years on average, earnings per share has increased by 28% per year but the company’s share price has fallen by 39% per year, which means it is significantly lagging earnings.お知らせ • Apr 14Waverley Pharma Inc., Annual General Meeting, Jun 24, 2026Waverley Pharma Inc., Annual General Meeting, Jun 24, 2026. Location: manitopa, Canadaお知らせ • Apr 14Waverley Pharma Inc., Annual General Meeting, Jun 23, 2025Waverley Pharma Inc., Annual General Meeting, Jun 23, 2025. Location: manitopa, winnipeg Canadaお知らせ • Sep 24Waverley Pharma Inc. (TSXV:WAVE) entered into a definitive agreement to acquire C & R Pharmacy, LLC for $0.51 million.Waverley Pharma Inc. (TSXV:WAVE) entered into a definitive agreement to acquire C & R Pharmacy, LLC for $0.51 million on September 18, 2024. A cash consideration of $0.45 million will be paid by Waverley Pharma Inc. Waverley Pharma Inc. will pay up to an additional $0.06 million cash after one year, if certain performance metrics are met. Waverley Pharma Inc. intends to finance the acquisition of C&R Pharmacy with current working capital on hand.Reported Earnings • Aug 28First half 2024 earnings released: CA$0.011 loss per share (vs CA$0.011 loss in 1H 2023)First half 2024 results: CA$0.011 loss per share (in line with 1H 2023). Net loss: CA$609.0k (loss widened 4.9% from 1H 2023).最新情報をもっと見るRecent updatesお知らせ • Jul 18Waverley Pharma Inc. Announces CFO Changes, Effective July 24, 2026Waverley Pharma Inc. announced that Haaris Uddin is resigning from his role as Chief Financial Officer (CFO) of the Company effective July 24, 2026 in order to pursue a professional opportunity outside the pharmaceutical industry. James Kinley, who is currently a director of the Company, has been named interim CFO and will assume the duties of Mr. Uddin upon his departure. Mr. Kinley is a Chartered Professional Accountant (CPA, CA) and an experienced CFO in the life science industry.Reported Earnings • May 24First quarter 2026 earnings released: CA$0.003 loss per share (vs CA$0.001 loss in 1Q 2025)First quarter 2026 results: CA$0.003 loss per share (further deteriorated from CA$0.001 loss in 1Q 2025). Revenue: CA$287.1k (down 27% from 1Q 2025). Net loss: CA$165.5k (loss widened 359% from 1Q 2025). Over the last 3 years on average, earnings per share has increased by 28% per year but the company’s share price has fallen by 39% per year, which means it is significantly lagging earnings.お知らせ • Apr 14Waverley Pharma Inc., Annual General Meeting, Jun 24, 2026Waverley Pharma Inc., Annual General Meeting, Jun 24, 2026. Location: manitopa, Canadaお知らせ • Apr 14Waverley Pharma Inc., Annual General Meeting, Jun 23, 2025Waverley Pharma Inc., Annual General Meeting, Jun 23, 2025. Location: manitopa, winnipeg Canadaお知らせ • Sep 24Waverley Pharma Inc. (TSXV:WAVE) entered into a definitive agreement to acquire C & R Pharmacy, LLC for $0.51 million.Waverley Pharma Inc. (TSXV:WAVE) entered into a definitive agreement to acquire C & R Pharmacy, LLC for $0.51 million on September 18, 2024. A cash consideration of $0.45 million will be paid by Waverley Pharma Inc. Waverley Pharma Inc. will pay up to an additional $0.06 million cash after one year, if certain performance metrics are met. Waverley Pharma Inc. intends to finance the acquisition of C&R Pharmacy with current working capital on hand.Reported Earnings • Aug 28First half 2024 earnings released: CA$0.011 loss per share (vs CA$0.011 loss in 1H 2023)First half 2024 results: CA$0.011 loss per share (in line with 1H 2023). Net loss: CA$609.0k (loss widened 4.9% from 1H 2023).お知らせ • Jun 21Waverley Pharma Inc. Elects James Kinley as DirectorWaverley Pharma Inc. at its annual and special meeting of shareholders held on June 20, 2024, elected James Kinley as director to hold office until the next annual meeting of shareholders or until their successor is duly elected. James Kinley, is the only newly appointed director. Mr. Kinley is a Chartered Professional Accountant (CPA, CA) with more than 15 years experience building, leading and advising companies through their daily operations as well as complex restructurings, mergers, acquisitions and capital market transactions. He is currently the Chief Financial Officer of Algernon Pharmaceuticals Inc. and a director of Medicure Inc. Both are publicly traded companies based in Canada.Reported Earnings • Jun 04First quarter 2024 earnings released: CA$0.005 loss per share (vs CA$0.006 loss in 1Q 2023)First quarter 2024 results: CA$0.005 loss per share (improved from CA$0.006 loss in 1Q 2023). Net loss: CA$264.1k (loss narrowed 22% from 1Q 2023). Over the last 3 years on average, earnings per share has fallen by 38% per year but the company’s share price has fallen by 55% per year, which means it is performing significantly worse than earnings.Reported Earnings • May 01Full year 2023 earnings released: CA$0.041 loss per share (vs CA$0.012 loss in FY 2022)Full year 2023 results: CA$0.041 loss per share (further deteriorated from CA$0.012 loss in FY 2022). Revenue: CA$412.1k (down 67% from FY 2022). Net loss: CA$2.22m (loss widened 235% from FY 2022).お知らせ • Apr 21Waverley Pharma Inc., Annual General Meeting, Jun 20, 2024Waverley Pharma Inc., Annual General Meeting, Jun 20, 2024.Board Change • Jan 23Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 2 non-independent directors. Independent Director Peter Enns was the last independent director to join the board, commencing their role in 2016. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Reported Earnings • Nov 29Third quarter 2023 earnings released: CA$0.006 loss per share (vs CA$0.002 loss in 3Q 2022)Third quarter 2023 results: CA$0.006 loss per share (further deteriorated from CA$0.002 loss in 3Q 2022). Revenue: CA$96.1k (down 72% from 3Q 2022). Net loss: CA$310.0k (loss widened 155% from 3Q 2022). Over the last 3 years on average, earnings per share has fallen by 9% per year but the company’s share price has fallen by 48% per year, which means it is performing significantly worse than earnings.お知らせ • Nov 24Waverley Pharma Inc. Announces Changes to Board of DirectorsWaverley Pharma Inc. announced that effective November 22, 2023, LarryThiessen has been appointed to the Company's Board of Directors. Mr.Thiessen replaces Hellen Siwanowicz, who has resigned from her board position. Mr. Thiessen is the current Chief Executive Officer of the Company and has extensive pharmaceutical experiencehaving previously worked for Bausch Health Companies Inc. (formerly Biovail Corporation), for more than 25years, working his way up from manager to site director of the manufacturing operation in Steinbach, Manitoba.He led a team of roughly 400 employees and provided overall leadership and strategic direction at the operation.Mr. Thiessen has a Bachelor of Science in Biology and an Executive M.B.A. from Athabasca University inEdmonton, Alberta.Board Change • Oct 10Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. Independent Director Helen Siwanowicz was the last director to join the board, commencing their role in 2017. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Reported Earnings • Aug 17Second quarter 2023 earnings released: CA$0.004 loss per share (vs CA$0 in 2Q 2022)Second quarter 2023 results: CA$0.004 loss per share (further deteriorated from CA$0 in 2Q 2022). Revenue: CA$148.6k (down 65% from 2Q 2022). Net loss: CA$241.0k (loss widened CA$216.9k from 2Q 2022).お知らせ • May 30Waverley Pharma Inc., Annual General Meeting, Jun 21, 2023Waverley Pharma Inc., Annual General Meeting, Jun 21, 2023, at 11:00 Central Daylight. Location: 4-1250 Waverley Street Winnipeg Manitoba Canada Agenda: To consider to receive and consider the audited financial statements of the Corporation for the period ended December 31, 2022 together with the auditors’ report thereon; to consider to elect three directors for the upcoming year, namely Dr. Albert D. Friesen, Hellen Siwanowicz, and P. Marcus Enns; to consider to appoint auditors for the upcoming year and to authorize the directors to fix the remuneration to be paid to the auditors; to consider to re-approve the Corporation’s 10% rolling Stock Option Plan; and to transact such further or other business as may properly come before the Meeting or any adjournment thereof.Reported Earnings • Apr 30Full year 2022 earnings released: CA$0.012 loss per share (vs CA$0.015 loss in FY 2021)Full year 2022 results: CA$0.012 loss per share (improved from CA$0.015 loss in FY 2021). Revenue: CA$1.25m (down 29% from FY 2021). Net loss: CA$664.1k (loss narrowed 17% from FY 2021).Board Change • Mar 10Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. Independent Director Helen Siwanowicz was the last director to join the board, commencing their role in 2017. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.お知らせ • Jan 12Waverley Pharma Inc. Provides Update on its PARP-1 Inhibitor ProgramWaverley Pharma Inc. provided an update on the status of its oncology focused PARP-1 inhibitor program. Based on growing interest in new PARP-1 inhibitors with selective activity against PARP-1 over PARP-2, the Company has renewed its focus on completing its PARP-1 pre-clinical development program, which is at the lead optimization stage. The current lead compound has single digit nanomolar activity and significant selectivity to PARP-1 over PARP-2. It is postulated that the effect of chemotherapy and radiation therapy is dampened by DNA repair enzymes 1 Poly (ADP-Ribose) Polymerase-1 (PARP-1) which belongs to the PARP family of enzymes and is involved in the detection and repair of DNA damage. PARP-1 inhibitors are a class of anti-cancer agents targeting DNA repair mechanism. The inhibition of PARP-1 is of clinical importance in various types of cancer. PARP-1 inhibitors have shown great potential to target high-grade ovarian cancers and triple-negative breast cancers which are resistant to current treatment. PARP-1 inhibitors can be used as a monotherapy to selectively kill cancer cells and in combination with other therapies.Reported Earnings • Nov 26Third quarter 2022 earnings released: CA$0.002 loss per share (vs CA$0.004 loss in 3Q 2021)Third quarter 2022 results: CA$0.002 loss per share (improved from CA$0.004 loss in 3Q 2021). Revenue: CA$341.9k (down 11% from 3Q 2021). Net loss: CA$121.7k (loss narrowed 41% from 3Q 2021).Board Change • Nov 23Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. Independent Director Helen Siwanowicz was the last director to join the board, commencing their role in 2017. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Board Change • Sep 14Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. Independent Director Helen Siwanowicz was the last director to join the board, commencing their role in 2017. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Reported Earnings • Jun 01First quarter 2022 earnings released: CA$0.006 loss per share (vs CA$0.003 loss in 1Q 2021)First quarter 2022 results: CA$0.006 loss per share (down from CA$0.003 loss in 1Q 2021). Revenue: CA$303.9k (down 16% from 1Q 2021). Net loss: CA$311.0k (loss widened 79% from 1Q 2021).Board Change • May 31Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. Independent Director Helen Siwanowicz was the last director to join the board, commencing their role in 2017. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Board Change • Sep 16Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. Independent Director Helen Siwanowicz was the last director to join the board, commencing their role in 2017. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.Reported Earnings • May 28First quarter 2021 earnings released: CA$0.003 loss per share (vs CA$0.003 loss in 1Q 2020)The company reported a solid first quarter result with reduced losses, improved revenues and improved control over expenses. First quarter 2021 results: Revenue: CA$360.0k (up 6.2% from 1Q 2020). Net loss: CA$173.9k (loss narrowed 4.7% from 1Q 2020).株主還元5GZDE BiotechsDE 市場7D-60.0%-0.1%0.1%1Y-50.0%11.4%-0.5%株主還元を見る業界別リターン: 5GZ過去 1 年間で11.4 % の収益を上げたGerman Biotechs業界を下回りました。リターン対市場: 5GZは、過去 1 年間で-0.5 % のリターンを上げたGerman市場を下回りました。価格変動Is 5GZ's price volatile compared to industry and market?5GZ volatility5GZ Average Weekly Movement28.9%Biotechs Industry Average Movement7.7%Market Average Movement5.3%10% most volatile stocks in DE Market12.7%10% least volatile stocks in DE Market2.7%安定した株価: 5GZの株価は、 German市場と比較して過去 3 か月間で変動しています。時間の経過による変動: 5GZの weekly volatility ( 29% ) は過去 1 年間安定していますが、依然としてGermanの株式の 75% よりも高くなっています。会社概要設立従業員CEO（最高経営責任者ウェブサイト2014n/aLarry Thiessenwww.waverleypharma.comバイオ医薬品企業であるWaverley Pharma Inc.は、英国でがん治療薬の研究、開発、商業化を行なっている。また、ジェネリックの注射剤にも注力している。同社は、テモゾロミド、カペシタビン、エルロチニブなどのジェネリックがん治療薬を提供している。また、非小細胞肺がんなどを適応症とするペメトレキセド、多発性骨髄腫などを適応症とするボルテゾミブなどの注射用ジェネリック化学療法薬も提供している。また、がん治療のためのPARP-1阻害剤も開発している。Waverley Pharma Inc.は2014年に設立され、カナダのウィニペグに本社を置いている。もっと見るWaverley Pharma Inc. 基礎のまとめWaverley Pharma の収益と売上を時価総額と比較するとどうか。5GZ 基礎統計学時価総額€337.00k収益（TTM）-€392.29k売上高(TTM)€777.22k0.4xP/Sレシオ-0.9xPER（株価収益率5GZ は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計5GZ 損益計算書（TTM）収益CA$1.25m売上原価CA$780.42k売上総利益CA$464.98kその他の費用CA$1.09m収益-CA$628.60k直近の収益報告Mar 31, 2026次回決算日該当なし一株当たり利益（EPS）-0.012グロス・マージン37.34%純利益率-50.47%有利子負債／自己資本比率-121.7%5GZ の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/07/23 02:45終値2026/07/23 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Waverley Pharma Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • Jul 18Waverley Pharma Inc. Announces CFO Changes, Effective July 24, 2026Waverley Pharma Inc. announced that Haaris Uddin is resigning from his role as Chief Financial Officer (CFO) of the Company effective July 24, 2026 in order to pursue a professional opportunity outside the pharmaceutical industry. James Kinley, who is currently a director of the Company, has been named interim CFO and will assume the duties of Mr. Uddin upon his departure. Mr. Kinley is a Chartered Professional Accountant (CPA, CA) and an experienced CFO in the life science industry.
Reported Earnings • May 24First quarter 2026 earnings released: CA$0.003 loss per share (vs CA$0.001 loss in 1Q 2025)First quarter 2026 results: CA$0.003 loss per share (further deteriorated from CA$0.001 loss in 1Q 2025). Revenue: CA$287.1k (down 27% from 1Q 2025). Net loss: CA$165.5k (loss widened 359% from 1Q 2025). Over the last 3 years on average, earnings per share has increased by 28% per year but the company’s share price has fallen by 39% per year, which means it is significantly lagging earnings.
お知らせ • Apr 14Waverley Pharma Inc., Annual General Meeting, Jun 24, 2026Waverley Pharma Inc., Annual General Meeting, Jun 24, 2026. Location: manitopa, Canada
お知らせ • Apr 14Waverley Pharma Inc., Annual General Meeting, Jun 23, 2025Waverley Pharma Inc., Annual General Meeting, Jun 23, 2025. Location: manitopa, winnipeg Canada
お知らせ • Sep 24Waverley Pharma Inc. (TSXV:WAVE) entered into a definitive agreement to acquire C & R Pharmacy, LLC for $0.51 million.Waverley Pharma Inc. (TSXV:WAVE) entered into a definitive agreement to acquire C & R Pharmacy, LLC for $0.51 million on September 18, 2024. A cash consideration of $0.45 million will be paid by Waverley Pharma Inc. Waverley Pharma Inc. will pay up to an additional $0.06 million cash after one year, if certain performance metrics are met. Waverley Pharma Inc. intends to finance the acquisition of C&R Pharmacy with current working capital on hand.
Reported Earnings • Aug 28First half 2024 earnings released: CA$0.011 loss per share (vs CA$0.011 loss in 1H 2023)First half 2024 results: CA$0.011 loss per share (in line with 1H 2023). Net loss: CA$609.0k (loss widened 4.9% from 1H 2023).
お知らせ • Jul 18Waverley Pharma Inc. Announces CFO Changes, Effective July 24, 2026Waverley Pharma Inc. announced that Haaris Uddin is resigning from his role as Chief Financial Officer (CFO) of the Company effective July 24, 2026 in order to pursue a professional opportunity outside the pharmaceutical industry. James Kinley, who is currently a director of the Company, has been named interim CFO and will assume the duties of Mr. Uddin upon his departure. Mr. Kinley is a Chartered Professional Accountant (CPA, CA) and an experienced CFO in the life science industry.
Reported Earnings • May 24First quarter 2026 earnings released: CA$0.003 loss per share (vs CA$0.001 loss in 1Q 2025)First quarter 2026 results: CA$0.003 loss per share (further deteriorated from CA$0.001 loss in 1Q 2025). Revenue: CA$287.1k (down 27% from 1Q 2025). Net loss: CA$165.5k (loss widened 359% from 1Q 2025). Over the last 3 years on average, earnings per share has increased by 28% per year but the company’s share price has fallen by 39% per year, which means it is significantly lagging earnings.
お知らせ • Apr 14Waverley Pharma Inc., Annual General Meeting, Jun 24, 2026Waverley Pharma Inc., Annual General Meeting, Jun 24, 2026. Location: manitopa, Canada
お知らせ • Apr 14Waverley Pharma Inc., Annual General Meeting, Jun 23, 2025Waverley Pharma Inc., Annual General Meeting, Jun 23, 2025. Location: manitopa, winnipeg Canada
お知らせ • Sep 24Waverley Pharma Inc. (TSXV:WAVE) entered into a definitive agreement to acquire C & R Pharmacy, LLC for $0.51 million.Waverley Pharma Inc. (TSXV:WAVE) entered into a definitive agreement to acquire C & R Pharmacy, LLC for $0.51 million on September 18, 2024. A cash consideration of $0.45 million will be paid by Waverley Pharma Inc. Waverley Pharma Inc. will pay up to an additional $0.06 million cash after one year, if certain performance metrics are met. Waverley Pharma Inc. intends to finance the acquisition of C&R Pharmacy with current working capital on hand.
Reported Earnings • Aug 28First half 2024 earnings released: CA$0.011 loss per share (vs CA$0.011 loss in 1H 2023)First half 2024 results: CA$0.011 loss per share (in line with 1H 2023). Net loss: CA$609.0k (loss widened 4.9% from 1H 2023).
お知らせ • Jun 21Waverley Pharma Inc. Elects James Kinley as DirectorWaverley Pharma Inc. at its annual and special meeting of shareholders held on June 20, 2024, elected James Kinley as director to hold office until the next annual meeting of shareholders or until their successor is duly elected. James Kinley, is the only newly appointed director. Mr. Kinley is a Chartered Professional Accountant (CPA, CA) with more than 15 years experience building, leading and advising companies through their daily operations as well as complex restructurings, mergers, acquisitions and capital market transactions. He is currently the Chief Financial Officer of Algernon Pharmaceuticals Inc. and a director of Medicure Inc. Both are publicly traded companies based in Canada.
Reported Earnings • Jun 04First quarter 2024 earnings released: CA$0.005 loss per share (vs CA$0.006 loss in 1Q 2023)First quarter 2024 results: CA$0.005 loss per share (improved from CA$0.006 loss in 1Q 2023). Net loss: CA$264.1k (loss narrowed 22% from 1Q 2023). Over the last 3 years on average, earnings per share has fallen by 38% per year but the company’s share price has fallen by 55% per year, which means it is performing significantly worse than earnings.
Reported Earnings • May 01Full year 2023 earnings released: CA$0.041 loss per share (vs CA$0.012 loss in FY 2022)Full year 2023 results: CA$0.041 loss per share (further deteriorated from CA$0.012 loss in FY 2022). Revenue: CA$412.1k (down 67% from FY 2022). Net loss: CA$2.22m (loss widened 235% from FY 2022).
お知らせ • Apr 21Waverley Pharma Inc., Annual General Meeting, Jun 20, 2024Waverley Pharma Inc., Annual General Meeting, Jun 20, 2024.
Board Change • Jan 23Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 2 non-independent directors. Independent Director Peter Enns was the last independent director to join the board, commencing their role in 2016. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Reported Earnings • Nov 29Third quarter 2023 earnings released: CA$0.006 loss per share (vs CA$0.002 loss in 3Q 2022)Third quarter 2023 results: CA$0.006 loss per share (further deteriorated from CA$0.002 loss in 3Q 2022). Revenue: CA$96.1k (down 72% from 3Q 2022). Net loss: CA$310.0k (loss widened 155% from 3Q 2022). Over the last 3 years on average, earnings per share has fallen by 9% per year but the company’s share price has fallen by 48% per year, which means it is performing significantly worse than earnings.
お知らせ • Nov 24Waverley Pharma Inc. Announces Changes to Board of DirectorsWaverley Pharma Inc. announced that effective November 22, 2023, LarryThiessen has been appointed to the Company's Board of Directors. Mr.Thiessen replaces Hellen Siwanowicz, who has resigned from her board position. Mr. Thiessen is the current Chief Executive Officer of the Company and has extensive pharmaceutical experiencehaving previously worked for Bausch Health Companies Inc. (formerly Biovail Corporation), for more than 25years, working his way up from manager to site director of the manufacturing operation in Steinbach, Manitoba.He led a team of roughly 400 employees and provided overall leadership and strategic direction at the operation.Mr. Thiessen has a Bachelor of Science in Biology and an Executive M.B.A. from Athabasca University inEdmonton, Alberta.
Board Change • Oct 10Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. Independent Director Helen Siwanowicz was the last director to join the board, commencing their role in 2017. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Reported Earnings • Aug 17Second quarter 2023 earnings released: CA$0.004 loss per share (vs CA$0 in 2Q 2022)Second quarter 2023 results: CA$0.004 loss per share (further deteriorated from CA$0 in 2Q 2022). Revenue: CA$148.6k (down 65% from 2Q 2022). Net loss: CA$241.0k (loss widened CA$216.9k from 2Q 2022).
お知らせ • May 30Waverley Pharma Inc., Annual General Meeting, Jun 21, 2023Waverley Pharma Inc., Annual General Meeting, Jun 21, 2023, at 11:00 Central Daylight. Location: 4-1250 Waverley Street Winnipeg Manitoba Canada Agenda: To consider to receive and consider the audited financial statements of the Corporation for the period ended December 31, 2022 together with the auditors’ report thereon; to consider to elect three directors for the upcoming year, namely Dr. Albert D. Friesen, Hellen Siwanowicz, and P. Marcus Enns; to consider to appoint auditors for the upcoming year and to authorize the directors to fix the remuneration to be paid to the auditors; to consider to re-approve the Corporation’s 10% rolling Stock Option Plan; and to transact such further or other business as may properly come before the Meeting or any adjournment thereof.
Reported Earnings • Apr 30Full year 2022 earnings released: CA$0.012 loss per share (vs CA$0.015 loss in FY 2021)Full year 2022 results: CA$0.012 loss per share (improved from CA$0.015 loss in FY 2021). Revenue: CA$1.25m (down 29% from FY 2021). Net loss: CA$664.1k (loss narrowed 17% from FY 2021).
Board Change • Mar 10Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. Independent Director Helen Siwanowicz was the last director to join the board, commencing their role in 2017. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
お知らせ • Jan 12Waverley Pharma Inc. Provides Update on its PARP-1 Inhibitor ProgramWaverley Pharma Inc. provided an update on the status of its oncology focused PARP-1 inhibitor program. Based on growing interest in new PARP-1 inhibitors with selective activity against PARP-1 over PARP-2, the Company has renewed its focus on completing its PARP-1 pre-clinical development program, which is at the lead optimization stage. The current lead compound has single digit nanomolar activity and significant selectivity to PARP-1 over PARP-2. It is postulated that the effect of chemotherapy and radiation therapy is dampened by DNA repair enzymes 1 Poly (ADP-Ribose) Polymerase-1 (PARP-1) which belongs to the PARP family of enzymes and is involved in the detection and repair of DNA damage. PARP-1 inhibitors are a class of anti-cancer agents targeting DNA repair mechanism. The inhibition of PARP-1 is of clinical importance in various types of cancer. PARP-1 inhibitors have shown great potential to target high-grade ovarian cancers and triple-negative breast cancers which are resistant to current treatment. PARP-1 inhibitors can be used as a monotherapy to selectively kill cancer cells and in combination with other therapies.
Reported Earnings • Nov 26Third quarter 2022 earnings released: CA$0.002 loss per share (vs CA$0.004 loss in 3Q 2021)Third quarter 2022 results: CA$0.002 loss per share (improved from CA$0.004 loss in 3Q 2021). Revenue: CA$341.9k (down 11% from 3Q 2021). Net loss: CA$121.7k (loss narrowed 41% from 3Q 2021).
Board Change • Nov 23Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. Independent Director Helen Siwanowicz was the last director to join the board, commencing their role in 2017. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Board Change • Sep 14Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. Independent Director Helen Siwanowicz was the last director to join the board, commencing their role in 2017. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Reported Earnings • Jun 01First quarter 2022 earnings released: CA$0.006 loss per share (vs CA$0.003 loss in 1Q 2021)First quarter 2022 results: CA$0.006 loss per share (down from CA$0.003 loss in 1Q 2021). Revenue: CA$303.9k (down 16% from 1Q 2021). Net loss: CA$311.0k (loss widened 79% from 1Q 2021).
Board Change • May 31Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. Independent Director Helen Siwanowicz was the last director to join the board, commencing their role in 2017. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Board Change • Sep 16Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. Independent Director Helen Siwanowicz was the last director to join the board, commencing their role in 2017. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
Reported Earnings • May 28First quarter 2021 earnings released: CA$0.003 loss per share (vs CA$0.003 loss in 1Q 2020)The company reported a solid first quarter result with reduced losses, improved revenues and improved control over expenses. First quarter 2021 results: Revenue: CA$360.0k (up 6.2% from 1Q 2020). Net loss: CA$173.9k (loss narrowed 4.7% from 1Q 2020).
